DeepMed Research

Fudan University

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Established: 1905-01-01

Employees: 1K

Market Cap: -

Website: http://www.fudan.edu.cn

Clinical Trials

ScreenIng of Genetic Susceptibility Genes for Breast Cancer Patients in CHinese communiTies

Recruiting

Conditions: Genetic Susceptibility
Breast Cancer

First Posted Date: 2020-02-12

Last Posted Date: 2023-05-31

Lead Sponsor: Fudan University

Target Recruit Count: 5000

Registration Number: NCT04265937

Locations: 🇨🇳
Zhen Hu, Shanghai, Shanghai, China

Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Melanoma

Phase 2

Conditions: Melanoma Stage IIIB-IV

Interventions: Drug: Toripalimab

First Posted Date: 2020-01-30

Last Posted Date: 2020-01-30

Lead Sponsor: Fudan University

Target Recruit Count: 100

Registration Number: NCT04248387

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients

Phase 1

Conditions: Neurocognitive Impairment

Interventions: Drug: Docosahexaenoic acid (DHA) capsules
Dietary Supplement: Soy oil capsules

First Posted Date: 2020-01-27

Last Posted Date: 2020-01-27

Lead Sponsor: Fudan University

Target Recruit Count: 88

Registration Number: NCT04242004

Locations: 🇨🇳
Department of epidemiology, School of public health, Fudan University,, Shanghai, Shanghai, China

Study on Predictive Biomarkers of Neoadjuvant Chemoradiotherapy for Rectal Cancer

Conditions: Rectal Neoplasm Malignant Carcinoma
Chemoradiotherapy
Predictive Biomarkers
Adenocarcinoma
Neoadjuvant Therapy

Interventions: Radiation: Radiation
Drug: Capecitabine-Irinotecan Combination

First Posted Date: 2020-01-14

Last Posted Date: 2020-01-14

Lead Sponsor: Fudan University

Target Recruit Count: 250

Registration Number: NCT04227886

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Nab-P and Gem Compared With Gem and Tegafur in Adjuvant Chemotherapy After Radical Resection of Pancreatic Cancer

Phase 2

Conditions: Stage IA Pancreatic Adenocarcinoma
Stage IB Pancreatic Adenocarcinoma
Stage IIA Pancreatic Adenocarcinoma
Stage IIB Pancreatic Adenocarcinoma

Interventions: Drug: nab-paclitaxel
Drug: tegafur
Drug: Gemcitabine

First Posted Date: 2020-01-03

Last Posted Date: 2020-06-30

Lead Sponsor: Fudan University

Target Recruit Count: 300

Registration Number: NCT04216758

Locations: 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China, Shanghai, China

Efficacy and Safety of Paclitaxel Liposome and S-1 as First-line Therapy in \ Advanced Pancreatic Cancer Patients

Phase 4

Conditions: Advanced Pancreatic Cancer

Interventions: Drug: Paclitaxel liposome
Drug: S-1

First Posted Date: 2020-01-03

Last Posted Date: 2020-01-03

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT04217096

Locations: 🇨🇳
Department of Pancreatic and Hepatobiliary Surgery, Fudan University Shanghai Cancer Center; Pancreatic Cancer Institute, Fudan University; 270 Dong An Road, Shanghai 200032, China, Shanghai, China

A Clinical Trial of Breast Cancer Neo-adjuvant Therapy Based on Molecular Pathway in FUSCC

Phase 1

Recruiting

Conditions: Breast Cancer

Interventions: Drug: A
Drug: B
Drug: CL4

First Posted Date: 2020-01-02

Last Posted Date: 2024-06-06

Lead Sponsor: Fudan University

Target Recruit Count: 20

Registration Number: NCT04215003

Locations: 🇨🇳
Shao Zhimin, Shanghai, Please Select, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Chidamide Combined With Cisplatin for Relapsed or Metastatic Triple-negative Breast Cancer

Phase 2

Conditions: Triple-negative Breast Cancer

Interventions: Drug: Chidamide combined with Cisplatin

First Posted Date: 2019-12-10

Last Posted Date: 2022-04-20

Lead Sponsor: Fudan University

Target Recruit Count: 55

Registration Number: NCT04192903

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

Phase 3

Conditions: Breast Cancer

Interventions: Drug: Epirubicin
Drug: Paclitaxel
Drug: Cyclophosphamide
Drug: Carboplatin
Drug: Docetaxel
Drug: Trastuzumab
Drug: Pertuzumab

First Posted Date: 2019-12-10

Last Posted Date: 2020-03-09

Lead Sponsor: Fudan University

Target Recruit Count: 1560

Registration Number: NCT04193059

Locations: 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China

HRCT in Prediction of Tumor Invasion in GGO Lung Adenocarcinoma (ECTOP-1008)

Completed

Conditions: Adenocarcinoma of Lung

First Posted Date: 2019-11-18

Last Posted Date: 2023-07-21

Lead Sponsor: Fudan University

Target Recruit Count: 620

Registration Number: NCT04165759

Locations: 🇨🇳
Fudan University Cancer Center, Shanghai, Shanghai, China
🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy